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Calcium activated adenylyl cyclase AC8
but not AC1 is required for prolonged
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Abstract
Background: Anxiety disorder is a state of mental discomfort while acute anxiety induces an enhancement of
vigilance/arousal or increased anxious responses. Most of the previous studies investigated basic mechanisms for
acute anxiety, while less information is available for prolonged or repetitive anxiety.
Results: In the present study, we wanted to examine possible molecular mechanisms for behavioral anxiety after
repeated exposures. Performing a paradigm of five sessions of the elevated plus-maze (EPM), we show that the
repeated exposure to the EPM induces a long-lasting anxiety causing a gradual increase of anxiolytic activity, which is
maintained for at least 21 days. Genetic deletion of AC8 (adenylyl cyclase 8) but not AC1 abolished long-lasting anxiety.
Conclusions: Our results suggest that calcium-stimulated AC8 is required to sustain the long-lasting anxiety caused by
repeated EPM testing, and we can identify in AC8 a novel target for treating anxiety-related mood disorders.
Keywords: Anxiety, Elevated plus-maze, Anterior cingulate cortex, Adenylyl cyclase 8, Retest, Memory,
N-Methyl-D-aspartate
Background
Acute anxiety is a functional process activated when the
organism finds itself in a potentially dangerous environ-
ment, allowing the central and sensory nervous system
to work in a sub-threshold state and carry out behaviors
such as fight-flight or freeze, thus to preserve its survival
and wellbeing. However, chronic or long-term anxiety
(also known as pathological anxiety) is a maladaptive
state in which this alert condition is maintained (due to
an inability to evaluate the danger of certain circum-
stances), causing unsuitable responses to the environ-
ment and affecting the daily life of the organism. Both
pathological and non-pathological forms represent one
of the most prevalent forms of mental discomfort with
detrimental economic impact [1]. Several studies have
found that chronic anxiety can be elicited or be closely
related to other physiological factors: stress response [2],
chronic pain [3, 4] and different types of mental disor-
ders [5, 6].
Previous studies, in which rodents were retested on
EPM, have shown a reduced or absent anxiolytic re-
sponse to benzodiazepines [7, 8], a phenomenon known
as “one trial tolerance”. These results have outlined the
hypothesis that a repeated experience in the EPM could
be related with a form of learning memory or a fear
component [9, 10]. Cyclic adenosine monophosphate
(cAMP) is a well-known second messenger for different
forms of memory-related, long-term plasticity [11]. The
production of cAMP can be mediated by different sub-
types of ACs. Among the ten isoforms, AC1 and AC8
are two neuronal isoforms in the CNS. AC1 has been
demonstrated to contribute to behavioral sensitization in
animal models with chronic pain [12–14], AC8 is less
sensitive to Ca2+ than AC1 [15], and it has been sug-
gested to be involved in stress-related anxiety [16]. How-
ever, there is no report of the possible contribution of
AC1 or AC8 to repetitive anxiety.
In the present study, we have carried out five sessions
of the EPM test in a single day, providing the first evi-
dence that repeated EPM phenotype could induce a
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form of sustained anxiety, which is greater than that
compared to mice submitted to a single EPM at 24 h
later and persists for at least 21 days later. Performing a
different anxiety test, such as the open field, after five re-
peated sessions of EPM, we confirm that our paradigm




Experiments conducted in accordance with protocols ap-
proved by the Animal Care Committee of the University
of Toronto (Canada). All efforts were made to minimize
animal suffering and the number of animals used. In most
of the experiments, we used adult male C57BL/6 J mice
(20–25 g) purchased from Charles River Charles River La-
boratories (St. Constant, Quebec, Canada). AC1 KO and
AC8 KO mice were generated as described previously and
bred for several generations (F12 to F16) to maintain the
C57BL/6 J genetic background [13]. All mice were housed
4 per cage, under a standard 12/12 h light/dark cycle with
food and water ad libitum.
Animal behavioral tests
Elevated plus-maze
The EPM test was performed as previously described
[17]. Mice were acclimatized to the room for 30 min be-
fore behavioral observation. The EPM (Med Associates,
St. Albans, Vermont) consisted of two open arms (250
lux) and two closed arms (35 lux) situated opposite to
each other. For each test, individual animals were placed
in the center square and allowed to move freely for
5 min. An observer, sitting quietly 1.5 m from the maze,
measured the number of entries, and time spent in each
arm was recorded. The maze was cleaned with ethanol
70 % and Virox® after each mouse was tested. For the
purpose of analysis: a) open-arm activity was quantified
as a percentage of the ratio between the time spent in
the open arms and the total time spent in the elevated
plus-maze (time open arms/total time × 100), b) the
number of entries into open arms as the sum of them,
and c) the total number of entries as the sum of entries
into the closed and open arms (entries open + entries
closed = total entries). The entry in the arm was consid-
ered as such when a mouse crossed the same with all
four paws. Mice, having undergone five sessions of the
repeated EPM, were tested for 5 min every 30 min. After
the first session of EPM, all mice were individually
housed until the beginning of the second session. This
group of mice was retested after 24 h from the last (fifth)
session. A different group of mice was exposed to a sin-
gle EPM and retested after 24 h.
Open field
The mice were exposed to an open field box, a Plexiglas®
square white box (43.2 × 43.2 × 30.5 cm3; Med Associ-
ates, St. Albans, Vermont) for 30 min and their loco-
motor activity was monitored by Activity Monitor
system from Med Associates (St. Albans, VT). Briefly,
this system used paired sets of photo beams to detect
movement in the open field and movement was
recorded as beam breaks (number of photo beams: 16;
space between the beams: 2.5 cm; number of zones: X:
17, Y: 17). The open field was placed inside an isolation
chamber with dim illumination. Each subject was placed
in the corner of the open field. The central zone was de-
fined as an area: start (X = 4; Y = 4), end (X = 12; Y = 12).
Different groups of mice C57Bl/6, either naïve or under-
gone five sessions of the repeated EPM, were tested on
open field 1 h after the last session.
Drugs
(+)-MK 801 maleate, threo ifenprodil hemitartrate, pur-
chased from Tocris Cookson (Avonmouth, Bristol, UK),
and naloxone hydrochloride dehydrate (Sigma-Aldrich,
St. Louis, MO) were dissolved in 0.9 % saline which,
alone, served as vehicle control. The stock of nimodipine
was dissolved in ethyl acetate and successively diluted in
a solution of Tween® 80 (5 %) used alone as control. The
pH of all solutions has been controlled.
Drug administration
All injections were performed intraperitoneally (i.p.),
30 min before the first session of the test, in a volume of
10 ml/kg, and doses cited refer to the salts.
Data analysis and statistic
Data are reported as mean ± standard error of mean
(SEM). Statistical analysis was carried out using the
One-Way analysis of variance for repeated measure (RM
ANOVA) for the internal statistic of each group,
followed by post-hoc Tukey test. Statistical analysis of
differences between two groups was performed by a
Two-Way ANOVA followed by post-hoc Tukey test
(Sigma Plot 12.5). p values <0.05 were considered statis-
tically significant.
Results
Five sessions of repeated EPM as a paradigm to cause
prolonged anxiety
Using the EPM test we explore the possibility that mice
(n = 22) tested every 30 min for five times in the EPM
can undergo a form of prolonged anxiety, which is main-
tained either 24 h or 21 days later (Fig. 1 A, B1). One-
way repeated measures analysis of variance (One Way
RM ANOVA) in mice submitted to this paradigm, shows
significant changes in the percentage of time spent in
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open arms when we compare the first two sessions of
EPM with the others (Fig. 1 B1) (p < 0.001 vs. 1° session
and p < 0.05 vs. 2° session). The reduction of the per-
centage of time spent in open arms is maintained either
in 24 h (n = 22) or 21 days sessions (n = 10). Further-
more, also the second session of EPM displays a sub-
stantial decrement in the percentage of time spent in
open arms if correlated with the first one (p < 0.05; 1° vs.
2° session, F (6, 114) = 31.82).
Exploration, locomotor activities and anxiety, repre-
sented as number of total and open arms entries, show a
strong reduction in the five daily sessions. The 24 h later
session displays diminished values of total and open en-
tries, which are comparable with those in the fifth trial.
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Fig. 1 Paradigm of five sessions of repeated EPM test and behavioral comparison vs one session of EPM. A) C57/Bl mice were tested in the EPM
apparatus for 5 min. The interval between each session is 30 min. Mice were retested after 24 h. A group of mice (n = 10) has been evaluated
after 21 days. Vehicle or drugs were injected 30 min before the first session. B1) Mice were tested in the elevated plus-maze apparatus for 5 min.
The interval between each session was 30 min. Black circular symbols are means ± SEM (error bars) of 22 mice per session. A group of 10 mice
were retested after 21 days. Single (*) or double asterisk (**) indicates a significant difference respectively from the (first/first and second) session.
B2) Black bars indicate the number of total entries (closed and open) in the arms (means ± SEM represented by error bars) of 22 mice per session.
Red bars represent the number (means ± SEM symbolized by error bars) of the entries in the open arms of the same groups in the same sessions.
Mice were retested after 24 h. A group of 10 mice were used in the session of 3 weeks. (*/***/****) indicate a significant difference respectively
from the (first/first, second and 3 weeks/first, second, third and 3 weeks) session. The hashes (#/##) represent a significant difference in the open
arms entries from the (first/first and second) session in the same groups. C1) Mice undergoing five repeated sessions of EPM (black circles; means ±
SEM, as error bar) and one time in the EPM (white triangles; means ± SEM, as error bar), both retested after 24 h, are compared. Significant difference,
inside the single EPM group, is represented with the (*). The (#) shows a significant difference between single and repeated EPM group for the same
session. C2) Black and blue bars represent the number of the total entries (means ± SEM, as error bar) in the first session and after 24 h of mice tested
five repeated times or one time in the EPM. Red and striped bars represent the number of the entries in the open arms (means ± SEM, as error bar) of
the same groups in the first and 24 h later session. The (*) indicates a significant difference of the same parameter inside the same group (same bar
color) before after 24 h. The (#) indicates a significant difference for the same parameter between the two groups after 24 h
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After 3 weeks these parameters are still significantly de-
creased but proportional to the second session of EPM.
From these data we can assert that the level of anxiety
induced in mice with our paradigm, increases over each
session, reaching a significant value already in the sec-
ond one, and a partial recovery is present only in the last
trial, when mice rediscover a greater locomotor activity
and propensity for exploration (Fig. 1 B2) (p < 0.001 vs.
1°, 2°, 7° session; p < 0.05 vs. 3° session; F (6, 114) = 143.12,
total entries; p < 0.001 vs. 1° session; p < 0.05 vs. 2° ses-
sion; F (6, 114) = 42.13, open entries). The continuous
avoidance of the open arms, along all sessions of the
paradigm, clarifies the impossibility of mice to habituate
themselves to repeated exposures.
A different group of ten mice were tested in the EPM for
only one session and retested after 24 h. When we compare
the two trials, a significant change of percentage of time
spent in open arms is present within this group (Fig. 1 C1)
(p < 0.05 vs. 1° session; F (1, 9) = 13.31). The session after
24 h, when compared with the same one of mice that have
undergone five repeated EPMs, displays an indicative differ-
ence (control vs. 1 EPM= p < 0.05 in 6° session; F (1, 60) =
42.12). These results show that a single trial on the EPM is
sufficient to affect the level of anxiety of a second trial 24 h
later, and highlights, above all, that mice submitted to five
repeated sessions of EPM, in a single day, have a drastic
reduction of percentage of time spent in open arms after
24 h that is a greater compared to mice having a single
experience in the EPM.
A single experience in EPM was not able to change com-
pletely the locomotor activity, in fact the entries in the total
arms between the first and the session 24 later are compar-
able (Fig. 1 C2) (p > 0.05 vs. 1° session; F (1, 9) = 4.80, total
entries). A single exposition to EPM, instead, is sufficient to
reduce the number of entries in the open arms after 24 h
(p < 0.05 vs. 1° session; F (1, 9) = 22.22, open entries). Both
the number of entries in the total and open arms, com-
pared with the parameters for the same session of mice
tested five times, are significantly greater (control vs. 1
EPM= p < 0.001 in 6° session; F (1, 60) = 102.15, total entries;
p < 0.05 in 6° session; F (1, 60) = 53.27, open entries). The re-
sults emphasize how repeated experiences in the EPM can
strongly reduce the exploration of the arms and increase
the anxiety-like behavior, while mice which have undergone
a single session maintain a great propensity for exploration
and a lower level of anxiety.
We performed the open field test on naïve mice and
those which have previously undergone a five -time re-
peated EPM, to investigate more in-depth anxiety-related
behaviors and to assess novel environment exploration or
the general locomotor activity [18]. Software related to the
open field test reported, for each mouse tested one time
for 30 min, both the travel distance of the central and total
zone and the spontaneous activities.
Comparing the travel distance, a measure of exploratory
behavior, of the two groups during the first few minutes in
the central zone, we were able to assess the exploration of a
novel environment and to analyze the anxiety-like behavior
[12]. Dividing the duration of the test in time bins of 5 min
(Fig. 2 A1), we found that mice which had undergone re-
peated EPM travelled less distance compared to naïve ones
(repeated EPM mice: 463.05 ± 90.08 cm vs. naïve: 675.28 ±
80.69 cm; p < 0.05; F (5, 180) = 5.34; 0-5 min) juxtaposed also
by less time spent (Fig. 2 A5), in the central area during the
first 5 min (repeated EPM mice: 5.66 ± 0.86 s vs. naïve:
9.00 ± 1.15 s; p < 0.05; F (5, 180) = 10.71; 0-5 min).
Extending the statistical comparison of the travel dis-
tance to all the 5-min intervals of the central or total zone,
we examined the habituation to an increasingly familiar
environment which shows a strong reduction along the
duration of the test in the group of mice which previously
endured up to five times EPM (Fig. 2 A1, B1). The de-
creased exploration and locomotor activity are verifiable
from the paths in the maps, which are less dense (Fig. 2
E1, E2). We also scored spontaneous activities which pro-
vide measures of the level of interest in the novelty of the
environment, and of general physical motor abilities.
These different parameters include vertical (rearing), am-
bulatory (horizontal fast activity), stereotypic (when the
animal is moving with the presence of repetitive, invariant
behaviors such as grooming, rearing and head bobbing
thus to break the same beam or set of beams), jumping
(escape latency) counts and entries. The significant differ-
ence of behavioral changes obtained during the open field
test consistently confirms that mice that have previously
undergone repeated EPM manifest an increased anxiety
which is heavily increased mostly in the last 15 min of the
test, when the environment should become more familiar.
NMDA receptors in the paradigm of prolonged behavioral
anxiety
In order to exclude an involvement of learning and
memory, a process NMDA receptor-mediated [19] and
to confirm the anxiolytic effect of the antagonist MK-
801 [20], we have administered, to a group of 16 mice, a
dose of 0.25 mg/kg, i.p., 30 min before the beginning of
the repeated EPM test (Fig. 3 A1). Two way ANOVA +
Tukey post hoc evidences significant differences in the
time spent in the open arms of the first and the second
session of mice treated with a single dose of MK-801 i.p.
compared with the control group (control vs. +MK-801
= p < 0.001 vs. 1° and 2° session; F (5, 216) = 29.48). Signifi-
cant changes are present in the percentage of time spent
in open arms of the first and second sessions when com-
pared to the others of the same group (p > 0.05, 1° vs. 2°
session; p < 0.001, vs. 1° and 2° session; p < 0.05, 2° vs. 3°
session; F (5, 75) = 18.58). The analysis of the number of
entries in the total arms (Fig. 3 A2) clearly shows that
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Fig. 2 Behavioral assessment of naïve mice or undergone to five sessions repeated EPM in the open field. Blue and red circles (means ± SEM, as
error bar) represent: A1- B1) the traveled distance (cm), A2- B2) the vertical counts (n), A3- B3) the ambulatory counts (n), A4- B4) the stereotypic
counts (n), A5- B5) the time of travelling (s) in the central zone (A) or total zone (B) over 30 min of test by naïve mice or undergone to five
repeated sessions of EPM. Significant difference within each time bin of 5 min, between the two groups, is represented with (*). C1) the number
of entries (n), D1) the jump counts (n) in the open field over 30 min of test by naïve mice or undergone to five repeated sessions of EPM are
represented with blue and red circles (means ± SEM, as error bar). Significant difference within each time bin of 5 min, between the two groups,
is represented with an asterisk (*). E1- E2) Representative traces show the movement of naïve or undergone to five repeated sessions of EPM
mice in the open field test over 30 min
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Fig. 3 (See legend on next page.)
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MK-801, at this dosage, influences the locomotor activity
inducing hyperactivity. From the plot, MK-801, in fact,
seems also to cause an amnesic effect, affecting the
spatial orientation and increasing significantly, when
compared with the control group, the exploration of the
arms in the EPM in all daily sessions and 24 h later
(control vs. +MK-801 = p > 0.05, in 1° session; p < 0.001
in 2°, 3°, 4°, 6° session; p < 0.05 in 5° session; F (5, 174) =
29.49, total entries). MK-801 reduces its effect, but is
still significant if compared with control mice, only in
the fifth session of the total entries (control vs. +MK-
801 = p < 0.05, 1° and 2° vs. 5° session; F (5, 40) = 4.81,
total entries). Mice treated with MK-801 display a sig-
nificant decrement in the number of entries in the open
arms after the second session (p > 0.05, 1° vs. 2° session;
p < 0.001, vs. 1° and 2° session; p < 0.05, 2° vs. 3° session;
F (5, 75) = 20.57, open entries). Comparing the same
parameter between MK-801-treated and control mice, the
drug shows no more significant outcomes from the ses-
sion subsequent to the third (control vs. +MK-801 = p <
0.001 in 1°, 2°, 3° session; F (5, 216) = 33.69, open entries).
During the behavioral experiments, due to their com-
plex pharmacological profile, the NMDA receptor antago-
nists could produce several adverse motor effects:
increased locomotor activity, turning behavior, head weav-
ing, body rolling, and stereotyped motor patterns [21]. To
avoid these outcomes, we have evaluated the importance
of NR2B, which has been proved to be involved in anxiety,
through the Tyr-1472 phosphorylation [22], in fear mem-
ory [23] but does not affect the spatial memory in the
Morris water maze test [24]. We have injected nine mice
with a dosage of ifenprodil of 10 mg/kg i.p. 30 min before
the first session (Fig. 3 B1). At this concentration the
NR2B antagonist does not induce any change in the time
spent in the open arms, which seems to be similar to the
control group (control vs. + ifenprodil 10 mg/kg = p > 0.05
in all sessions; F (5, 174) = 25.56), while the internal statis-
tical analysis of the group presents important differences
between the first and the second sessions when compared
with the others (p < 0.001, 1° vs. 5°, 6° session; p < 0.05, 1°
vs. 3°, 4° session; p < 0.05, 2° vs. 5° session; F (5, 40) = 7.94).
From the plot (Fig. 3 B2) we can appreciate how the
ifenprodil, correlated with the control group, negatively
affects the locomotor activity in the first session, while
in the 24 h later session, it increases the total entries
(control vs. + ifenprodil 10 mg/kg = p < 0.001, in 1° ses-
sion; p > 0.05 in 2°, 3°, 4°, 5° session; p < 0.05 in 6° ses-
sion; F (5, 174) = 104.02, total entries). The entries in the
open arms, on the other hand, maintain values compar-
able to control group (control vs. + ifenprodil 10 mg/kg
= p > 0.05 in all sessions; F (5, 174) = 45.88, open entries).
The statistic inside the group of mice treated with ifen-
prodil displays a reduction, either in total or open arms
entries, from the first to the fifth session (p < 0.001, all
vs. 1° session; p < 0.001, 2° vs. 5°, 4° session; p < 0.05, 2°
vs. 3° session; p < 0.05, 6° vs. 5° session; p < 0.05, 3° vs. 5°
session; F (5, 40) = 35.61, total entries; p < 0.001, 1° vs. 5°,
4°, 3°, 6° session; p < 0.05, 1° vs. 2° session; p < 0.05, 2° vs.
5°, 4° session; F (5, 40) = 18.25, open entries).
A second group of ten mice were treated with a higher
dosage of ifenprodil 20 mg/kg i.p. 30 min before the test
(Fig. 3 C1). Time in the open arms is significantly
(See figure on previous page.)
Fig. 3 Behavioral effect of drug treatment in mice submitted to five times repeated EPM test. We compare different sessions in mice treated with
a single injection i.p. of: A1) (+) MK-801 (0.25 mg/kg), B1) ifenprodil (10 mg/kg), C1) ifenprodil (20 mg/kg), D1) nimodipine (10 mg/kg), E1) naloxone (5 mg/kg),
30 min before and the same sessions between control and treated mice tested five times in the EPM and retested after 24 h. Black circular symbols and white
triangles are means ± SEM (error bars) of control and injected mice per session. In A1) the (**) indicates a significant difference from the first and the second
session of the same group. The (#) indicates a significant difference between control and treated mice in the same session. In B1) the (*/**) indicate a
significant difference, within the ifenprodil group, between the first and the second session and the others. No significant difference is detected
between control and treated mice of the same session. In C1) the (*/**) indicate a significant difference, within ifenprodil group, from the (first/first and
second) session of the same group (same symbol). The (#) indicates a significant difference between control and treated mice for the same session. In
D1) the (*) indicates a significant difference between the first session and the others within nimodipine group. The (#) indicates a significant difference
between control and treated mice of the same session. In E1) the (*) indicates a significant difference, within the naloxone group, from the first session
of the same group (same symbol). The (#) indicates a significant difference between control and treated mice in the same session. Number of entries
in total arms of control mice and mice treated with a single injection i.p. of: A2) (+) MK-801, B2) ifenprodil, C2) ifenprodil, D2) nimodipine, E2) naloxone,
are represented with black and blue bars (means ± SEM). Red and striped bars express respectively the number (means ± SEM) of the entries in the
open arms of control mice and treated mice. In A2) the (**) indicates a significant difference of the same parameter compared to first and second
session of the same group (same bar color). The (#) indicates a significant difference of the same behavioral parameters between the same sessions of
the two groups. In B2) the (*/**/****) on the blue and striped bar indicate a significant difference respectively from the (first/first and second/first,
second, third and 24 h) session of the same group (same bar color). The (#) indicates a significant difference from the control group of the behavioral
parameters in the same session. In C2) the (*/**/***/****) on the blue and striped bar indicate a significant difference respectively from the (first/first
and second/first, second, and 24 h/first, second, third and 24 h) session of the same group (same bar color). The (#) indicates a significant difference of
the behavioral parameters from the control group in the same session. In D2) the (*) on the blue and striped bar indicates a significant difference in
the entries between the first and the other sessions of the same group (same bar color). The (#) indicates a significant difference from the control
group in the behavioral parameters of the same session. In E2) the (*/**/***) on the blue and striped bar indicate a significant difference respectively
from the (first/first and second/first, second, third) session of the same group (same bar color). The (#) indicates a significant difference of the behavioral
parameters from the control group in the same session
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increased in the second session (control vs. + ifenprodil
20 mg/kg = p < 0.05, in 2° session; p > 0.05 in 1°, 3°, 4°, 5°,
6° session; F (5, 210) = 44.00), after which the percentage
of time spent in open arms become, for each session,
comparable to the control group. The comparison of
each session shows that the last four sessions are heavily
diminished (p < 0.001, 1° vs. 5°, 4°, 3°, 6° session; p < 0.001,
2° vs. 5°, 4° session; p < 0.05, 2° vs. 3°, 6° session; F (5, 70) =
15.55). At this dosage ifenprodil (Fig. 3 C2) has no effect
in the number of total entries along the five consecutive
sessions, but greatly increases the same dimension in the
24 h later trial (control vs. + ifenprodil 20 mg/kg = p <
0.001 in 6° session; p > 0.05 in 1°, 2°, 3°, 4°, 5° session; F (5,
210) = 167.30, total entries). The treatment seems to ameli-
orate the anxiety increasing the entries in the open arms
of the first trial, but without affecting remaining ones
(control vs. + ifenprodil 20 mg/kg = p < 0.001 in 1° session;
p > 0.05 in 2°, 3°, 4°, 5°, 6° session; F (5, 210) = 78.01, open
entries). The internal comparison of the total entries in-
side the groups manifests a clear decrease along the ses-
sions (blue bars) with a slight increase on the 24 h later
trial, which is comparable to the third one (p < 0.001, 1°
vs. all sessions; p < 0.001, 2° vs. 3°, 4°, 5° session; p < 0.05,
2° vs. 6° session; p < 0.001, 6° vs. 5°, 4° session; p < 0.05, 3°
vs. 5° session, F (5, 70) = 86.61, total entries). The entries in
the open arms present an indicative differences when cor-
related with the first and the second session (p < 0.001, 1°
vs. all sessions; p < 0.001, 2° vs. 5° session; p < 0.05, 2° vs.
3°, 4° session; F (5, 70) = 33.83, open entries).
L-type voltage-gated calcium channels (L-VGCCs) in the
repeated EPM paradigm
To speculate the influence of calcium homeostasis in
anxiety-related behavior, we have injected an L-type
VGCCs blocker, a class of receptors which are also rec-
ognized to contribute to LTP in several areas of the
brain [25, 26], and which plays an important role in cued
fear conditioning [27] with no effect on the acquisition
of spatial, working and reference memory [28, 29].
An intraperitoneal administration of nimodipine
(10 mg/kg) in a group of eight mice 30 min before the
first session of repeated EPM is unable to reduce the
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Fig. 4 AC8 KO mice, but not AC1 KO, do not display a long-lasting anxiety-like behavior during the repeated EPM test. We compare different sessions
in: A1) AC1 KO, B1) AC8 KO mice group and the same sessions between control and KO mice tested five times in the EPM and retested after 24 h. Black
circular symbols and white triangles are means ± SEM (error bars) of control and KO mice per session. In A1) the (*) indicates a significant difference,
within AC1 KO group (same symbol) from the first session. The (#) indicates a significant difference between control and AC1 KO mice of the same
session. In B1) no significant difference is present within AC8 KO group (same symbol) along the entire test. The (#) indicates a difference between
control and AC8 KO mice of the same session. Black and blue bars represent the number (means ± SEM) of the total entries of control and A2) AC1 KO
mice, B2) AC8 KO mice. Red and striped bars represent respectively the number (means ± SEM) of the entries in the open arms of control and KO mice
in the same sessions. In A2) the (*/**/***) on the blue and striped bar indicate a significant difference respectively from the (first/first and second/first,
second, third) session of the same group (same bar color). No significant difference of the behavioral parameters from the control group in the same
session. In B2) the (*/**) on the blue and striped bar indicate a significant difference respectively from the (first/first and second) session of the same
group (same bar color). The (#) indicates a significant difference of the behavioral parameters from the control group in the same session
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anxiety behavior (Fig. 3 D1). Almost all sessions are
comparable to the control mice’s one, but conversely to
our expectations, in the second and third one, nimodi-
pine seems to increase the anxious responses (control
vs. + nimodipine = p < 0.001 in 2° session; p < 0.05 in 3°
session; p > 0.05 in 1°, 4°, 5°, 6° session; F (5, 168) = 27.58).
The internal statistic of the group treated with nimodi-
pine shows a remarkable difference only between the
first and the other sessions (p < 0.001, 1° vs. all sessions;
F (5, 35) = 9.72). From Fig. 3 D2 it is possible to appreciate
how, correlated to the control group, the nimodopine re-
duces the locomotor activity, the exploration and in-
crease the anxiety-related behavior until the third trial,
after which it returns to levels comparable to the control
mice (control vs. + nimodipine = p < 0.001 in 1°, 2° ses-
sion; p < 0.05 in 3° session; F (5, 168) = 61.21, total entries;
p < 0.001 in 1°, 2° session; p < 0.05 in 3° session; F (5, 168)
= 32.30, open entries). The statistical analysis of the mice
treated with nimodipine has shown an indicative decre-
ment of the values after the first session of both entries
in the total or open arms (p < 0.001, 1° vs. all sessions; F
(5, 35) = 12.03, total entries; p < 0.001, 1° vs. all sessions; F
(5, 35) = 8.93, open entries).
Effects of opioid antagonist naloxone
It is known that opioid receptors are linked with anxiety
by the use of genetic knockout mice [30, 31]. Activation
of opioid receptors are related to ACs [32]. We have
treated a group of 11 mice (Fig. 3 E1) with naloxone
(5 mg/kg, i.p.), an opioid antagonist (μ,δ,k). Statistical
analysis reveals a significant effect in the time spent in
the open arms, compared to the control group, only in
the first session with no effects on the others (control vs.
+ naloxone = p < 0.001 in 1° session; p > 0.05 in 2°, 3°, 4°,
5°, 6° session; F (5, 181) = 39.29). Statistical analysis of the
group indicates that there is a strong decrease of the ef-
fect after the first trial (p < 0.001, 1° vs. all sessions; F (5,
45) = 18.14).
Total entries (Fig. 3 E2) do not point out any differ-
ences in the locomotor activity of the control group
(control vs. + naloxone = p > 0.05, in all sessions; F (5,
181) = 123.67). A statistical reduction is evident in all the
sessions when compared with the first and the second
one (p < 0.001, 1° vs. all sessions; p < 0.001, 2° vs. 5°, 4°
session; p < 0.05, 2° vs. 3° session; F (5, 45) = 53.31, total
entries). The reduction of anxiety (Fig. 3 E2) in the first
session is confirmed by an increase, compared to the
control group, in the number of entries in the open arms
(control vs. + naloxone = p < 0.001 in 1° session, p > 0.05
in 2°, 3°, 4°, 5°, 6° session; F (5, 181) = 82.81). The statistic
inside the group notifies a decrease of number of entries
if compared with the first and the second trials (p <
0.001, 1° vs. all sessions; p < 0.05, 2° vs. 5°, 4° session; F
(5, 45) = 46.14, open entries).
Role of AC1 and AC8 in repeated EPM
While AC1 plays important role in pain-related LTP in
the ACC in mice [33] confirmed by the analgesic effects
of NB001 [12], an AC1inhibitor, and seems to reduce
anxiety induced by irritable bowel syndrome (IBS) [3],
studies in AC8 KO mice and single-nucleotide polymor-
phisms (SNPs) located in the AC8 (ADCY8) gene in
humans, restrict its involvement to mental disorders as
depression and anxiety [16, 34]. Using 29 AC1 KO mice
(Fig. 4 A1), we investigate the role of AC1 in this anxiety
test. Mice undergoing repeated EPM exhibit, if com-
pared to control group, an increment in the percentage
of time spent in open arms only the first session, with
no relevant differences in the other trials (control vs.
AC1KO = p < 0.05 in 1° session; p > 0.05 in 2°, 3°, 4°, 5°,
6° session; F (5, 290) = 26.92). The first two sessions of the
AC1 KO group present important changes compared
with the others (p < 0.001, 1° vs. all sessions; p < 0.05, 2°
vs. 5°, 6° session; F (5, 136) = 33.38).
Total entries in the arms and in the open arms display
no differences when compared to the control group (Fig.
4 A2), with values going down until the fifth one (control
vs. AC1KO = p > 0.05 in all sessions; F (5, 290) = 112.37,
total entries; p > 0.05 in all sessions; F (5, 290) = 59.16,
open entries). In the 24 h later session both the parame-
ters are comparable with those in the fourth one (p <
0.001, 1° vs. all sessions; p < 0.001, 2° vs. all sessions; p <
0.001, 3° vs. 5° session; p < 0.05, 6° vs. 5° session; F (5,
136) = 96.02, total entries; p < 0.001, 1° vs. all sessions; p <
0.001, 2° vs. 5° session; p < 0.05, 2° vs. 6°, 4° session; F (5,
136) = 47.15, open entries).
Performing the repeated EPM test on a group of
twenty-eight AC8 KO mice (Fig. 4 B1), we examine the
role of AC8. Surprisingly the percentage of time spent in
open arms is maintained constant along all the sessions
until 24 h later, when correlated with control group
(control vs. AC8KO= p < 0.001 in 3°, 4°, 5° session; p < 0.05
in 1°, 2°, 6° session; F (5, 288) = 4.14). The statistic inside the
group of the time in the open arms does not show any
change along the entire test (p > 0.05 in all sessions; F (5,
135) = 2.15). After the first session, either the total entries or
the entries in the open arms (Fig. 4 B2) show values re-
markably higher than the control ones (control vs. AC8KO
= p > 0.05 in 1° session; p < 0.05 in 2° session; p < 0.001 in
3°, 4°, 5°, 6° session; F (5, 246) = 92.01, total entries; p > 0.05
in 1° session; p < 0.05 in 2°, 5° session; p < 0.001 in 3°, 4°, 6°
session; F (5, 288) = 16.00, open entries). The statistical ana-
lysis inside the group highlights that the number of total
entries appears to decrease after the first two sessions (p <
0.001, 1° vs. all sessions; p < 0.001, 2° vs. 5° session; p < 0.05,
2° vs. 4°, 6°, 3° session; F (5, 100) = 32.24, total entries) while,
for the number of entries in the open arms, after the first
one (p < 0.001, 1° vs. 5° session; p < 0.05, 1° vs. 4°, 6°, 3° ses-
sion; F (5, 135) = 6.87, open entries).
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Discussion
The major findings of the present study are that: 1) mice
which have undergone five repeated EMP tests in a sin-
gle day displayed increased open arms avoidance, repre-
sented by a strong reduction in the percentage of time
spent in open arms and reduced number of entries in
total and open arms; 2) the significant decrease of per-
centage of time spent in open arms and entries, caused
by our paradigm, was maintained either 24 h or 21 days
later; 3) AC8 KO mice exhibit a less anxious phenotype
along all sessions of our paradigm; and 4) none of the
drugs tested produced an anxiolytic-like effect in our
paradigm. Using the open field as the second following
anxiety test, we confirm the changes in the level of anx-
iety. Due to the limited behavioral approach of our
study, we are not able to clarify the molecular mechan-
ism of this long-lasting anxiety-like behavior. Future
studies using both electrophysiological and biomolecular
techniques will be needed in studying in-depth some of
these aspects. We cannot rule out the possibility that
this form of sustained anxiety could trigger a de novo ex-
pression of AC8, a process present in the inflammatory
context of atherosclerosis [35].
A previous study, regarding the re-exposition on the
maze, attempted to explain this stronger open-arm avoid-
ance as the rodents’ incapacity to habituate to their innate
aversion to open spaces and heights [36]. The lack of anxio-
lytic response to benzodiazepines in retested mice on EPM,
known as “one trial tolerance” has promoted the hypothesis
that a repeated experience in the EPM could integrate a
specific phobia or learning memory component [9, 10].
While the first conjecture of the phobic avoidance of open
arms has been elegantly rejected performing a first trial
with a four-enclosed-arm elevated plus-maze and showing
that the “one-trial tolerance” phenomenon still persisted
during the second session [37], we have tried to clarify the
other unresolved issues elucidating better the magnitude
and the quality of the learning memory component in mice
submitted to a previous experience in the EPM. Initially, we
carried out a pharmacological approach focusing on the
possible targets related to LTP, one of the major cellular
molecular processes that participate on learning and mem-
ory formation [38]. We have considered as one of the pos-
sible main targets in our study, the NMDA receptors,
which mediate the induction of LTP and memory [39].
MK-801, a non-competitive NMDA receptor antagonist,
and ifenprodil, an antagonist more selective for NMDA re-
ceptors containing NR2B subunits, have displayed no sig-
nificant effect. Calcium is an important signaling messenger
for synaptic LTP [4, 40, 41], including postsynaptic NMDA
receptor dependent LTP and presynaptic LTP through L-
VGCCs [41–43]. L-VGCCs have been implicated in various
behavioral responses such as learning [44], spatial memory
[45], anxiety and fear [46]. However, we found that systemic
injection of nimodipine caused motor side effects, as shown
by a significant decrease of entries in either total or open
arms. Future studies are needed to determine its roles. The
μ- and δ- opioid receptors are important for pain, anxiety
and fear [30, 47]. cAMP pathways are linked to these func-
tions [48, 49]. Pharmacological inhibition or genetic dele-
tion of these receptors have displayed a capacity to impair
acquisition in several behavioral tests [50]. However, we
found that the administration of naloxone has no signifi-
cant effect.
Previous studies show that calcium-stimulated ACs, es-
pecially, AC8 is important for stress-related anxiety [16]. In
the present study, we also found that AC8 is essential for
long-term anxiety caused by repetitive EPMs. These results
consistently demonstrate that AC8 may be a potential key
signaling protein for different forms of anxiety. The exact
mechanism for AC8 involvement is unclear, and one pos-
sible synaptic mechanism is LTD. Schaefer et al. reported
that AC8 is required for hippocampal LTD induced by
low-frequency stimulation. It is known that AC8 is also
expressed at other brain regions [51], and it is possible that
AC8 may contribute to behavioral anxiety through other
brain regions. In addition, recent human studies suggest
that single-nucleotide polymorphism (SNPs) and mutation
on ADCY8 gene may link to anxiety or depression [16, 34].
In summary, our current findings provide strong evidence
that AC8 may serve as a potential drug target for the future
treatment of behavioral anxiety in patients.
Conclusions
In this study, we demonstrate that a paradigm of five re-
peated exposures to the elevated plus-maze (EPM) is
able to induce long-lasting anxiety, which is maintained
for at least 21 days. The lack of AC8 protein eliminates
this prolonged form of anxiety. The data reported in our
study suggest that AC8 can be considered a possible
suitable drug target for anxiety treatment. Future studies
will further clarify the electrophysiological and molecu-
lar mechanisms.
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